Specimen Requirements

Minimum Specimen Requirements

Stability

Days Performed

Sun - Sat

Turnaround Time

9 - 13 days

Methodology

Reference Range

Special Info

Reflex Algorithm: Each reflex test performed incurs additional charge. If the immunofluorescence (IFA) patterns suggest collapsin response-mediator protein-5-IgG (CRMP-5-IgG), then CRMP-5-IgG IFA titer and CRMP-5-IgG Western blot will be performed. If the IFA patterns suggest amphiphysin antibody, then amphiphysin IFA titer and amphiphysin immunoblot will be performed. If the IFA pattern suggests antiglial nuclear antibody (AGNA-1), then AGNA-1 IFA titer and AGNA-1 immunoblot will be performed. If the IFA pattern suggests antineuronal nuclear antibody type 1 (ANNA-1), then ANNA-1 IFA titer, ANNA-1 immunoblot, and ANNA-2 immunoblot will be performed. If the IFA pattern suggests ANNA-2 antibody, then ANNA-2 IFA titer, ANNA-1 immunoblot, and ANNA-2 immunoblot will be performed. If the IFA pattern suggests Purkinje cytoplasmic antibody type 1 (PCA-1), then PCA-1 IFA titer and PCA-1 immunoblot will be performed. If the IFA pattern suggests PCA-2 antibody, then PCA-2 IFA titer will be performed. If the IFA pattern suggests PCA-Tr antibody, then PCA-Tr IFA titer and PCA-Tr immunoblot will be performed. If IgLON5 cell-binding assay (CBA) is positive, then IgLON5 IFA titer will be performed. If AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor antibody CBA is positive, then AMPA-receptor antibody IFA titer assay will be performed. If gamma-aminobutyric acid B (GABA-B) receptor antibody CBA is positive, then GABA-B-receptor antibody IFA titer assay will be performed. If the IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then GFAP IFA titer and GFAP CBA will be performed. If N-methyl-D-aspartate (NMDA) receptor antibody CBA is positive, then NMDA-receptor antibody IFA titer assay will be performed. If DPPX antibody CBA is positive, then DPPX IFA titer will be performed. If the IFA pattern suggests metabotropic glutamate receptor 1 (mGluR1) antibody, then mGluR1 antibody CBA and mGluR1 IFA titer will be performed. If the IFA pattern suggests neuronal intermediate filament (NIF) antibody, then alpha internexin CBA, NIF heavy chain CBA, NIF light chain CBA, and NIF IFA titer will be performed. If the IFA pattern suggests neurochondrin antibody, then neurochondrin antibody CBA and neurochondrin IFA titer will be performed. If the IFA pattern suggests septin-7 antibody, then septin-7 antibody CBA and septin-7 IFA titer will be performed. If the indirect immunofluorescence (IFA) pattern suggests phosphodiesterase 10A (PDE10A) IgG, then the PDE10A antibody IFA titer will be performed. If the indirect immunofluorescence (IFA) pattern suggests tripartite motif-containing protein 46 (TRIM46) IgG, then TRIM46 antibody cell-binding assay (CBA) and IFA titer will be performed. Neuron-restricted patterns of IgG staining that do not fulfill criteria for ANNA-1, ANNA-2, ANNA-3, CRMP-5-IgG, PCA-1, PCA-2, or PCA-Tr may be reported as "unclassified anti-neuronal IgG." Complex patterns that include nonneuronal elements may be reported as "uninterpretable." Relevant clinical information, ordering provider name, phone number, mailing address, and e-mail address are required. Grossly hemolyzed, lipemic or icteric specimens will be rejected.

Clinical Info

Aids in evaluating new onset encephalopathy (noninfectious or metabolic) comprising confusional states, psychosis, delirium, memory loss, hallucinations, movement disorders, sensory or motor complaints, seizures, dyssomnias, ataxias, nausea, vomiting, inappropriate antidiuresis, coma, dysautonomias, or hypoventilation in spinal fluid specimens. A diagnosis of autoimmune encephalopathy should be suspected on the basis of clinical course, coexisting autoimmune disorder (eg, thyroiditis, diabetes), serological evidence of autoimmunity, spinal fluid evidence of intrathecal inflammation, neuroimaging or electroencephalographic abnormalities, and favorable response to trial of immunotherapy. Detection of one or more neural autoantibodies aids the diagnosis of autoimmune encephalopathy and may guide a search for cancer. Importantly, autoimmune encephalopathies are reversible. Misdiagnosis as a progressive (currently irreversible) neurodegenerative condition is not uncommon and has devastating consequences for the patient. Clinicians must consider the possibility of an autoimmune etiology in the differential diagnoses of encephalopathy.

Clinical Limitation

Specimens from pediatric patients are no longer accepted for the Autoimmune Encephalopathy Evaluation. The Autoimmune Pediatric CNS Disorders may be ordered as APCNSS for serum and APCNSC for CSF, or specific antibodies may be ordered directly: GAD65 Antibody, CSF (GADCSF); MOG IgG, Serum (MOGFAC).